Clinical trials: Nephropathy
Diabetic Nephropathy
A Phase 2 Multi-Center Study To Evaluate The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist In Adults With Type 2 Diabetes And Overt Nephropathy
The study hypothesis under test is that administration of a CCR2/5 antagonist to subjects with type 2 diabetes and overt nephropathy will result in a reduction in urinary albumin, a surrogate for improved glomerular filtration.
- Trial name
- NCT01712061
- Testing
- PF-04634817
- Where
- 142 sites in United States, Argentina and 12 more
- Volunteers
- 226 people
- Sponsor
- Pfizer
Contrast Induced Nephropathy
Statins for Prevention of Contrast Induced Nephropathy
In this randomized study the investigators wish to explore the role of pre-procedural statin therapy for the prevention of contrast induced nephropathy in patients with moderate-to-severe renal dysfunction, submitted to elective…
- Trial name
- NCT00770796
- Testing
- Atorvastatin
- Volunteers
- 304 people
- Sponsor
- Ospedale Misericordia e Dolce
Diabetic Nephropathy
To Assess the Accuracy of the eZscan Study in the Screening for Diabetic Nephropathy
Diabetes mellitus (DM) is a metabolic disorder commonly encountered by the healthcare professionals. Diabetic nephropathy is one of its complications, which is becoming the most common cause of end-stage renal failure in Hong…
- Trial name
- NCT01163591
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Chinese University of Hong Kong
Recurrent IgA Nephropathy
Rituximab in Recurrent IgA Nephropathy
Currently, the treatment options of recurrent IgA nephropathy (IgAN) are conflicting and largely based on expert opinions. Consequently, the recent KDIGO clinical practice guideline for the care of kidney transplant recipients…
- Trial name
- NCT02571842
- Testing
- Intravenous Rituximab, ACEI/ARB and corticosteroids
- Where
- Thailand
- Volunteers
- 30 people
- Sponsor
- Chulalongkorn University
Primary IgA Nephropathy
The Effect of Nefecon® in Patients With Primary IgA Nephropathy at Risk of Developing End-stage Renal Disease
The objective of the study is to evaluate efficacy and safety of two different doses of NEFECON in the treatment of patients with primary IgA nephropathy (IgAN) at risk of developing end-stage renal disease, under rigorous blood…
- Trial name
- NEFIGAN (NCT01738035)
- Testing
- NEFECON
- Where
- 58 sites in Belgium, Czechia and 8 more
- Volunteers
- 150 people
- Sponsor
- Calliditas Therapeutics AB
IgA Nephropathy
Supportive Versus Immunosuppressive Therapy for the Treatment Of Progressive IgA Nephropathy
Evaluation of the efficacy of an immunosuppressive therapy added to a comprehensive supportive therapy to induce a clinical remission in patients at risk for progressive IgAN Investigation of differences between the treatments…
- Trial name
- STOP-IgAN (NCT00554502)
- Testing
- supportive therapy with: ACE-inhibitor / ARB / Statin, supportive and immunosuppressive therapy
- Where
- 34 sites in Germany
- Volunteers
- 148 people
- Sponsor
- RWTH Aachen University
Diabetic Nephropathy
Safety, Tolerability and Pharmacokinetic Study of MT-3995 at a Low Dose in Subjects With Diabetic Nephropathy
The purpose of this study is to evaluate safety, tolerability and pharmacokinetics of MT-3995 in Subjects with Diabetic Nephropathy.
- Trial name
- NCT02205372
- Testing
- MT-3995
- Where
- Japan
- Volunteers
- 31 people
- Sponsor
- Tanabe Pharma Corporation
Renal Failure, Chronic, Diabetic Nephropathies
Glucose in Dialysis Water in Diabetics With Chronic Renal Failure
The purposes are 1. to measure the effect of dialysis with glucose in dialysis water on blood pressure, pulse rate, plasma concentration of glucose, plasma concentrations og insulin, glucagon, growth hormone, renin, angiotensin…
- Trial name
- NCT00438503
- Testing
- Procedure
- Where
- Denmark
- Volunteers
- 18 people
- Sponsor
- Regional Hospital Holstebro
Diabetic Kidney Disease
Very Low Calorie Diet for Diabetic Kidney Disease
The purpose of this study is to determine whether a very low calorie diet will stabilize or improve diabetic kidney disease.
- Trial name
- NCT01671969
- Testing
- very low calorie diet
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Indiana University
Type 2 Diabetes Mellitus, DM Nephropathy
Effects of Disease Management on Development of End Stage Renal Disease in Type 2 Diabetic Patients With Nephropathy
Disease management using a multidisciplinary team to achieve and maintain optimal metabolic and cardiovascular risk factors control in Type 2 diabetic patients with nephropathy reduces the incidence of end stage renal disease…
- Trial name
- NCT00309127
- Testing
- Multidisciplinary team care
- Where
- China
- Volunteers
- 205 people
- Sponsor
- Chinese University of Hong Kong
Nephropathy, Cardiovascular Diseases
The Effects of Atorvastatin on the Nitrogen Oxide-system in Patients With Type 2 Diabetes and Nephropathy
It has been documented that statin reduce mortality and morbidity in patients with cardiovascular disease. This effect can partly be related to a reduction in cholesterol levels in blood.
- Conditions
- Nephropathy, Cardiovascular Diseases, Diabetes Mellitus
- Trial name
- STAD (NCT01208701)
- Testing
- Atorvastatin, Unikalk
- Where
- Denmark
- Volunteers
- 25 people
- Sponsor
- Erling Bjerregaard Pedersen
Nephropathy, Cardiovascular Diseases
The Effects of Atorvastatin on the Nitric Oxide-system in Patients With Non-diabetic Nephropathy
It has been documented that statin reduce mortality and morbidity in patients with cardiovascular disease. This effect can partly be related to a reduction in cholesterol levels in blood.
- Trial name
- STAN (NCT01213498)
- Testing
- Atorvastatin, Unikalk
- Where
- Denmark
- Volunteers
- 25 people
- Sponsor
- Erling Bjerregaard Pedersen
IgA Nephropathy, Glomerular Diseases
Biomarkers for the Progression of IgA Nephropathy
IgA nephropathy (IgAN) is the most prevalent primary glomerular disease worldwide and an important cause of end stage renal disease.
- Trial name
- NCT02529722
- Where
- Turkey (Türkiye)
- Volunteers
- 120 people
- Sponsor
- Istanbul University
IgA Nephropathy
A Survey of Factors Affecting an Early or Delayed Diagnosis of IgA Nephropathy
This is a survey of factors which affect a pathologically defined early or delayed diagnosis of IgA nephropathy in Guangdong General Hospital, Guangzhou, China.
- Trial name
- NCT01538433
- Where
- China
- Volunteers
- 603 people
- Sponsor
- Guangdong Provincial People's Hospital
IgA Nephropathy
Paricalcitol for the Treatment of Immunoglobulin A Nephropathy
Immunoglobulin A (IgA) nephropathy is the common type of primary glomerulonephritis in the world. A wealth of literature suggests that vitamin D and its analogs have profound effects on immune system function and glomerular…
- Trial name
- NCT00599963
- Testing
- paricalcitol
- Where
- Hong Kong
- Sponsor
- Chinese University of Hong Kong
IgA Nephropathy
BRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy
The purpose of this study is to compare the effect of blisibimod plus standard of care versus placebo plus standard of care alone on the proportion of subjects achieving improvement in renal disease parameters.
- Trial name
- NCT02052219
- Testing
- Blisibimod
- Sponsor
- Anthera Pharmaceuticals
Focus Type 2 Diabetes Related Chronic Kidney Disease
Diabetic Kidney Disease: Influence of Exercise Therapy on Physical and Vascular Function.
The general objective is to investigate the effect of a 12 week walking exercise program on vascular endothelial function, arterial stiffness/compliance, and vascular health biomarkers in men and women with pre-dialysis type 2…
- Trial name
- DKD-EXT (NCT02112071)
- Testing
- Exercise
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- University of Minnesota
Diabetic Nephropathy
The Significance of Urine UbA52 In the Diagnosis of Diabetic Nephropathy
Definite diagnosis of diabetic nephropathy is currently based on renal biopsy findings. In most cases, however, the diagnosis can be reliably made in patients with macroalbuminuria in the presence of diabetic…
- Trial name
- NCT02204280
- Volunteers
- 120 people
- Sponsor
- Hebei Medical University Third Hospital
Lupus Nephritis, IgA Nephropathy
The Correlation of Periostin and Renal Pathology in Chronic Kidney Disease Patients
The purpose of this study is to determine the location of periostin and urine periostin level in patients with lupus nephritis and IgA nephropathy.
- Trial name
- NCT02493101
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Chulalongkorn University
IgA Nephropathy
Aliskiren for Proteinuric IgAN Despite Angiotensin Blockade
Study objective: To investigate the potential anti-proteinuric efficacy of aliskiren, a novel direct renin inhibitor (DRI), in addition to angiotensin receptor blocker (ARB) in immunoglobulin A nephropathy (IgAN) patients at risk…
- Trial name
- NCT00922311
- Testing
- Aliskiren
- Where
- 2 sites in China
- Volunteers
- 25 people
- Sponsor
- The University of Hong Kong